Hajdu–Cheney Syndrome, a Rare Cause of Acro‐Osteolysis and Osteoporosis With Zoledronic Acid Experience
American Journal of Medical Genetics Part A · 2025
DOI: 10.1002/ajmg.a.63985 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, 2025. Verfasst von Gonul Buyukyilmaz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology, Ankara Bilkent City Hospital, Ankara, Turkey. Hauptthemen laut MEDLINE: Hajdu-Cheney Syndrome, Zoledronic Acid, Receptor, Notch2, Osteoporosis. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Hajdu–Cheney syndrome (HCS), caused by a heterozygous gain of function variant of the NOTCH2 gene, is a rare skeletal dysplasia. Although the main presentation is acro‐osteolysis, osteoporosis, and facial dysmorphism, having a wide range of clinical manifestations creates diagnostic difficulties. Here, a 15‐year‐old male patient with HCS who had no complaints until this age except for two short bone fractures and one vertebral collapse fracture due to a fall was reported. The patient presented with acro‐osteolysis, facial anomalies, skull deformity, and osteoporosis. The clinical diagnosis of HCS was supported by a positive genetic test of a novel de novo heterozygous pathogenic variant in exon 34 of NOTCH2 c.6614dupAfs*. Zoledronic acid treatment was applied for 2 years, and the patient responded well to the treatment, showing signs of improved bone density and improvement in vertebral height. We identified a novel NOTCH2 gene variant related to HCS. Our findings could extend phenotypic spectrum and genotype–phenotype correlations. The results of this case report support that antiresorptive treatment with zoledronic acid increased bone mineral density. Nevertheless, because of the low prevalence of the syndrome and the small number of reported cases, further studies are required to understand the syndrome better and establish treatment guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Endocrinology, Ankara Bilkent City Hospital, Ankara, Turkey.
- Department of Radiology, Dr. Burhan Nalbantoğlu State Hospital, Nicosia, Cyprus.
- Department of Pediatric Endocrinology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey.
- Department of Pediatric Genetics, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
ORCID-Profile: Gonul Buyukyilmaz, Mehmet Adiguzel, Fatih Gurbuz, Esra Kılıc
Zitieren
APA
Buyukyilmaz, G., Adiguzel, M., Gurbuz, F., & Kılıc, E. (2025). Hajdu–Cheney Syndrome, a Rare Cause of Acro‐Osteolysis and Osteoporosis With Zoledronic Acid Experience. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63985
Vancouver
Buyukyilmaz G, Adiguzel M, Gurbuz F, Kılıc E. Hajdu–Cheney Syndrome, a Rare Cause of Acro‐Osteolysis and Osteoporosis With Zoledronic Acid Experience. American Journal of Medical Genetics Part A. 2025. doi:10.1002/ajmg.a.63985
BibTeX
@article{Buyukyilmaz2025,
author = {Buyukyilmaz, Gonul and Adiguzel, Mehmet and Gurbuz, Fatih and Kılıc, Esra},
title = {Hajdu–Cheney Syndrome, a Rare Cause of Acro‐Osteolysis and Osteoporosis With Zoledronic Acid Experience},
journal = {American Journal of Medical Genetics Part A},
year = {2025},
doi = {10.1002/ajmg.a.63985}
}
EUVIMED